Challenging the Treatment Paradigm for HER2-low Breast Cancer: Managed Care Perspectives

Challenging the Treatment Paradigm for HER2-low Breast Cancer: Managed Care Perspectives is organized by Pharmacy Times Continuing Education (PTCE),Release date: October 21, 2022,Expiration date: October 21, 2023,Description:,About 50% of all primary breast cancers show low-level expression of human epidermal growth factor receptor 2 (HER2). Until recently, little has been known about the prognostic value of low HER2 expression in metastatic breast cancer. Historically, HER2-targeted therapies were not effective in patients with HER2-low disease, so HER2-low was categorized and treated as HER2-negative. However, novel therapies are showing promise against HER2-low disease, prompting investigation into additional targeted treatment strategies. Predictive biomarkers are now essential in identifying HER2-low status and guiding treatment selection in specific patient populations. This program will discuss the safety and efficacy profiles of these novel therapies as well as biomarker testing. As the understanding of HER2-low breast cancer expands, managed care professionals must utilize the most current data to navigate the challenges of both diagnosing and treating this patient population. This program will examine the clinical impact of newly developed treatment strategies for patients with breast cancer with low HER2 expression, with a focus on implications for guideline recommendations and treatment pathways.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Explore the utility of current biomarker testing requirements to identify patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer.,• Analyze the safety and efficacy profiles of novel therapies for treating patients with HER2-low breast cancer.,• Identify the role of managed care in the evolving approach to diagnosing and treating HER2-low breast cancer.